432 related articles for article (PubMed ID: 34713680)
21. Duration of Heart Failure With Reduced Ejection Fraction Associated With Electrocardiographic Outcomes Before and After Sacubitril/Valsartan.
Lin PL; Lee YH; Liu LY; Tsai CT; Yang TF; Chiou WR; Hsieh MY; Chang HY; Huang CC
J Cardiovasc Pharmacol Ther; 2022; 27():10742484221107799. PubMed ID: 35713466
[TBL] [Abstract][Full Text] [Related]
22. Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study.
Carluccio E; Dini FL; Bitto R; Ciccarelli M; Correale M; D'Agostino A; Dattilo G; Ferretti M; Grelli A; Guida S; Jacoangeli F; Lupi L; Luschi L; Masarone D; Mercurio V; Pacileo G; Pugliese NR; Rispoli A; Scelsi L; Tocchetti CG; Brunetti ND; Palazzuoli A; Piepoli M; Nodari S; Ambrosio G;
Int J Cardiol; 2022 Mar; 350():62-68. PubMed ID: 34998946
[TBL] [Abstract][Full Text] [Related]
23. Short-term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan.
Mazzetti S; Scifo C; Abete R; Margonato D; Chioffi M; Rossi J; Pisani M; Passafaro G; Grillo M; Poggio D; Mortara A
ESC Heart Fail; 2020 Jun; 7(3):964-972. PubMed ID: 32233080
[TBL] [Abstract][Full Text] [Related]
24. Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.
Ibrahim NE; Piña IL; Camacho A; Bapat D; Felker GM; Maisel AS; Butler J; Prescott MF; Abbas CA; Solomon SD; Januzzi JL;
Circ Heart Fail; 2020 Nov; 13(11):e007829. PubMed ID: 33016100
[TBL] [Abstract][Full Text] [Related]
25. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
Chen F; Tian G; Bai X; Li J; Yuan Z
Ann Palliat Med; 2021 Aug; 10(8):8684-8691. PubMed ID: 34488357
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Usefulness of Myocardial Work in Patients With Heart Failure and Reduced Ejection Fraction Treated by Sacubitril/Valsartan.
Bouali Y; Donal E; Gallard A; Laurin C; Hubert A; Bidaut A; Leclercq C; Galli E
Am J Cardiol; 2020 Jun; 125(12):1856-1862. PubMed ID: 32305222
[TBL] [Abstract][Full Text] [Related]
27. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
[TBL] [Abstract][Full Text] [Related]
28. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients.
Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC
ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930
[TBL] [Abstract][Full Text] [Related]
29. Isovolumic Contraction Velocity in Heart Failure With Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: the PROVE-HF Study.
Omar AMS; Murphy S; Felker GM; Piña I; Butler J; Liu Y; Mohebi R; Bhatia K; Ward JH; Williamson KM; Solomon SD; Januzzi JL; Contreras J
J Card Fail; 2024 May; 30(5):653-665. PubMed ID: 37816446
[TBL] [Abstract][Full Text] [Related]
30. Effect of SAcubitril/Valsartan on left vEntricular ejection fraction and on the potential indication for Implantable Cardioverter Defibrillator in primary prevention: the SAVE-ICD study.
Guerra F; Ammendola E; Ziacchi M; Aspromonte V; Pellegrino PL; Del Giorno G; Dell'Era G; Pimpini L; Santoro F; Floris R; Stronati G; Nigro G; Paolisso P; Guido A; Maglia G; Brunetti ND; Carbone A; Gravellone M; Antonicelli R; Cannone M; Accogli M; Dello Russo A; Palmisano P
Eur J Clin Pharmacol; 2021 Dec; 77(12):1835-1842. PubMed ID: 34279677
[TBL] [Abstract][Full Text] [Related]
31. Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
Villani A; Ravaro S; Cerea P; Caravita S; Ciambellotti F; Branzi G; Munforti C; Parati G; Malfatto G
J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):682-687. PubMed ID: 32744827
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal Changes in Natriuretic Peptides and Reverse Cardiac Remodeling in Patients with Heart Failure Treated with Sacubitril/Valsartan Across the Left Ventricular Ejection Traction Spectrum.
Yamamoto M; Ishizu T; Sato K; Minami K; Terauchi T; Nakatsukasa T; Kawamatsu N; Machino-Ohtsuka T; Ieda M
Int Heart J; 2023 Nov; 64(6):1071-1078. PubMed ID: 37967975
[TBL] [Abstract][Full Text] [Related]
33. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
[TBL] [Abstract][Full Text] [Related]
34. Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience.
Monzo L; Gaudio C; Cicogna F; Tota C; Petronilli V; Mennuni S; De Ruvo E; Calò L
Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5690-5700. PubMed ID: 34604961
[TBL] [Abstract][Full Text] [Related]
35. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation.
Bayard G; Da Costa A; Pierrard R; Roméyer-Bouchard C; Guichard JB; Isaaz K
Int J Cardiol Heart Vasc; 2019 Dec; 25():100418. PubMed ID: 31517034
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study.
Aqel R; Alzughayyar TZ; Abukhalaf SA; Misk RA; Zalloum JS
J Renin Angiotensin Aldosterone Syst; 2021; 2021():1829873. PubMed ID: 35027945
[TBL] [Abstract][Full Text] [Related]
37. Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry.
Lund LH; Zeymer U; Clark AL; Barrios V; Damy T; Drożdż J; Fonseca C; Kalus S; Ferber PC; Koch C; Maggioni AP;
Int J Cardiol; 2023 Jan; 370():279-286. PubMed ID: 36216094
[TBL] [Abstract][Full Text] [Related]
38. Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
Murphy SP; Prescott MF; Camacho A; Iyer SR; Maisel AS; Felker GM; Butler J; Piña IL; Ibrahim NE; Abbas C; Burnett JC; Solomon SD; Januzzi JL
JACC Heart Fail; 2021 Feb; 9(2):127-136. PubMed ID: 33189632
[TBL] [Abstract][Full Text] [Related]
39. Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction.
Pericas P; Mas-Lladó C; Ramis-Barceló MF; Valadrón I; Noris Mora M; Pasamar Márquez L; González Colino R; Forteza Albertí JF; Peral Disdier V; Rossello X
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):167-175. PubMed ID: 33599965
[TBL] [Abstract][Full Text] [Related]
40. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]